Not bullet proof at all"The question of the importance of type I error (or p-values) in study design cannot be resolved here. However, we have presented a study design that transparently adheres to Bayesian principles of data synthesis, along with its frequentist operating characteristics and anticipate healthy debate about our approach when Tigris is complete and analyzed."
They want the FDA to look at the data their way, but that's not a given at all.